COVID-19: the use of immunotherapy in metastatic lung cancer

被引：19
作者：
Davis, Alexander P. [1 ]
Boyer, Michael [1 ,2 ]
Lee, Jenny H. [1 ,3 ]
Kao, Steven C. [1 ,2 ]
机构：
[1] Chris OBrien Lifehouse, Dept Med Oncol, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Macquarie Univ, Fac Med & Hlth, N Ryde, NSW 2109, Australia
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 08期
关键词：
COVID-19; duration of therapy; immune checkpoint inhibitors; immunotherapy; lung cancer; CHEMOTHERAPY;
D O I：
10.2217/imt-2020-0096
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：545 / 548
页数：4
相关论文
共 26 条
  • [1] How will country-based mitigation measures influence the course of the COVID-19 epidemic?
    Anderson, Roy M.
    Heesterbeek, Hans
    Klinkenberg, Don
    Hollingsworth, T. Deirdre
    [J]. LANCET, 2020, 395 (10228) : 931 - 934
  • [2] [Anonymous], 2017, ANN ONCOL S5
  • [3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [4] Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms
    Chen, YM
    Perng, RP
    Chu, H
    Tsai, CM
    Whang-Peng, J
    [J]. LUNG CANCER, 2004, 45 (01) : 39 - 43
  • [5] Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors
    Chong, Curtis R.
    Park, Vivian J.
    Cohen, Bevin
    Postow, Michael A.
    Wolchok, Jedd D.
    Kamboj, Mini
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 70 (02) : 193 - 199
  • [6] Chowell G, 2012, COMPUT MATH METHODS, V2012, P1
  • [7] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Yau, Thomas
    Crocenzi, Todd S.
    Kudo, Masatoshi
    Hsu, Chiun
    Kim, Tae-You
    Choo, Su-Pin
    Trojan, Jorg
    Welling, Theodore H., III
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    dela Cruz, Christine
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    Dastani, Homa B.
    Melero, Ignacio
    [J]. LANCET, 2017, 389 (10088) : 2492 - 2502
  • [8] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
  • [9] Herbst RS, 2020, JCLIN ONCOL
  • [10] Huang CL, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30211-7]
123